Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Aydanian A"'
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
Supplemental Table 1 describes the adverse events with corresponding risk differences between treatment arms during induction of pivotal trial ALFA-0701.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bd7a67b15c996ac2b4ce4780a377946
https://doi.org/10.1158/1078-0432.22470144
https://doi.org/10.1158/1078-0432.22470144
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
On September 1, 2017, the FDA granted approval for gemtuzumab ozogamicin (Mylotarg; Pfizer Inc.) in combination with daunorubicin and cytarabine and as a monotherapy for the treatment of adult patients with newly diagnosed CD33-positive acute myeloid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a3057e773121d0976ff70e8b3c1217f
https://doi.org/10.1158/1078-0432.c.6527439.v1
https://doi.org/10.1158/1078-0432.c.6527439.v1
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
Supplemental Table 4 and the accompanying text describe the grouped terms used for the adverse reactions described in Table 2 and the reasons for using grouped terms.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bfa00162775f4396f1aa89b2c0e5fca
https://doi.org/10.1158/1078-0432.22470135.v1
https://doi.org/10.1158/1078-0432.22470135.v1
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
Supplemental Table 2 describes the adverse events with corresponding risk differences between treatment arms during consolidation 1 of pivotal trial ALFA-0701.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2cceacb4b09d64994c9590265576d3f
https://doi.org/10.1158/1078-0432.22470141
https://doi.org/10.1158/1078-0432.22470141
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
Supplemental Table 3 describes the adverse events with corresponding risk differences between treatment arms during consolidation 2 of pivotal trial ALFA-0701.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60239a2a0c9573ca130b251dacba13e0
https://doi.org/10.1158/1078-0432.22470138.v1
https://doi.org/10.1158/1078-0432.22470138.v1
Autor:
Antonina Aydanian, Li Tang, Yuansha Chen, J. Glenn Morris Jr, Peter Olsen, Judith A. Johnson, G. Balakrish Nair, O. Colin Stine
Publikováno v:
International Journal of Infectious Diseases, Vol 37, Iss C, Pp 152-158 (2015)
Background: In an attempt to better understand the non-O1/O139 isolates of Vibrio cholerae, a systematic study of clinical and environmental isolates collected from various geographical locations between the years 1932 and 1998 was conducted. Methods
Externí odkaz:
https://doaj.org/article/a0805bd6b70e4f4dafb71d18e5b42033
Autor:
Azar, Rabih R., Badaoui, Georges, Sarkis, Antoine, Azar, Mireille, Aydanian, Herminé, Harb, Serge, Achkouty, Guy, Kassab, Roland
Publikováno v:
In The American Journal of Cardiology 2010 106(2):193-197
Autor:
Pallavi Garg, Antonia Aydanian, David W. Smith, J. Glenn Morris, G. Balakrish Nair, O. Colin Stine
Publikováno v:
Emerging Infectious Diseases, Vol 9, Iss 7, Pp 810-814 (2003)
Vibrio cholerae in O-group 139 was first isolated in 1992 and by 1993 had been found throughout the Indian subcontinent. This epidemic expansion probably resulted from a single source after a lateral gene transfer (LGT) event that changed the serotyp
Externí odkaz:
https://doaj.org/article/49524a0ef18b420898a97a852bb85087
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e106699 (2014)
Monoclonal antibodies are important tools in research and since the 1990s have been an important therapeutic class targeting a wide variety of diseases. Earlier methods of mAb production relied exclusively on the lengthy process of making hybridomas.
Externí odkaz:
https://doaj.org/article/81542b1db53c4071bc00d813cad542b5
Autor:
Emily Y. Jen, Jiang Liu, Lei Nie, Jee Eun Lee, Kelly J. Norsworthy, Ann T. Farrell, Donna Przepiorka, Pedro L. Del Valle, Charles Jewell, Antonina G. Aydanian, Chia-Wen Ko, Richard Pazdur, Christopher M. Sheth, Marjorie A. Shapiro
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(14)
On September 1, 2017, the FDA granted approval for gemtuzumab ozogamicin (Mylotarg; Pfizer Inc.) in combination with daunorubicin and cytarabine and as a monotherapy for the treatment of adult patients with newly diagnosed CD33-positive acute myeloid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e116f2798cff476caeef820993cec972
https://pubmed.ncbi.nlm.nih.gov/29476018
https://pubmed.ncbi.nlm.nih.gov/29476018